barinthusbio.comCrawled Nov 3, 2026
Vaccitech is a late-stage T cell immunotherapy company developing non-replicating viral vectors to treat and prevent cancer and infectious diseases.
Program: Celiac disease Stage: Preclinical Barinthus Biotherapeutics rights: Worldwide
Program: Prostate cancer immunotherapeutic Stage: Phase 1 Barinthus Biotherapeutics rights: Worldwide
Program: HBV immunotherapeutic Stage: Phase 2 Barinthus Biotherapeutics rights: Worldwide
Non-Executive DirectorAlex is Head of Corporate Finance at Oxford Science Enterprises (OSE) and a former physician. OSE is the £1.2bn venture capital firm partnered with Oxford University to identify and develop the University’s science and technology into category defining companies. Alex was a medical student and junior doctor in the Oxford training deanery before transitioning […]
Chief Executive Officer & Board DirectorWilliam “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several […]
Non-Executive DirectorDr. Phillips is the Senior Vice President, Clinical, Medical & Regulatory Affairs, North America Operations, for Novo Nordisk Inc., leading the drug development, clinical operations, medical, regulatory, health economics and outcomes research, and safety teams. Dr. Phillips has more than 25 years of healthcare experience, including serving as Vice President of Clinical Development at […]
CHIEF MEDICAL OFFICERDr. Leon Hooftman brings significant drug development expertise across a broad array of therapeutic areas including oncology, infectious diseases, and inflammation. His R&D portfolio includes successful clinical trial programs that resulted in the development of novel agents: mycophenolate mofetil (transplantation), rituximab (Non-Hodgkin’s Lymphoma), gemtuzumab ozogamycin (Leukemia), and lipid complex amphotericin B (serious fungal […]
The name Barinthus comes from a character named in legends relating to King Arthur of Britain, mentioned in Geoffrey of Monmouth’s Vita Merlini (Life of Merlin), written 1150 AD, in which the character is noted as a guide and navigator.
Barinthus Bio is an emerging leader in the research and development of antigen-specific immunotherapies that guide T cells to fight disease across I&I indications. We are building on a rich history of cutting-edge innovations by our scientific founders from leading institutions.
To help patients gain control over their disease, Barinthus Biotherapeutics is developing antigen-specific immunotherapies across I&I indications. Key aspects of these therapies are that they are designed to be specific to the disease and precisely engineered with the aim of either guiding a patient’s T cells to become regulatory T (Treg) cells that promote immune tolerance or effector T (Teff) cells that can be directed to eliminate virally infected or cancer cells.
Barinthus Biotherapeutics (UK) Ltd 3rd Floor 1 Ashley Road Altrincham, Cheshire WA14 2DT United Kingdom
Thank you for your interest in Barinthus Biotherapeutics and your enquiry about our ongoing clinical trials.
Barinthus Biotherapeutic induces T cells and antibodies to treat and prevent disease.
1.1. We (being the Barinthus Biotherapeutics plc group of companies, referred to as “The Group” hereafter) need to gather and use information or ‘data’ about you as part of our business and to manage our relationship with you. This policy sets out the things we must tell you about data protection.
We want to ensure that you enjoy browsing our website and have an excellent user experience. Therefore this website places “cookies” onto your computer to collect information about your use of our site.
